Twist Bioscience Adds Lilly TuneLab Collaboration to Antibody Discovery Efforts

What happened

Twist Bioscience announced a new agreement with Lilly TuneLab to advance antibody drug discovery, adding another pharma collaboration to its platform. The partnership fits the narrative of Twist as an AI-enabled drug discovery enabler, but the announcement lacks financial terms or revenue projections. The company's latest filings show robust revenue growth and improving gross margins, yet operating losses and cash burn remain elevated. The stock's 191% run-up over the past year has priced in aggressive expectations for AI-related monetization, and this news alone does not provide that proof. Investors should treat this as a minor positive that reinforces the strategic positioning but does not alter the fundamental wait-and-see stance until the next quarterly filing.

Implication

The Lilly TuneLab agreement adds another marquee pharma name to Twist's antibody discovery customer list, which could eventually lead to incremental revenue, but no financial terms are disclosed, so the near-term impact is likely negligible. The stock currently trades at a high multiple to revenue with negative earnings, and the market has already priced in a successful AI drug discovery monetization story. The key catalysts for re-rating remain unchanged: achieving adjusted EBITDA breakeven in Q4 FY26, sustaining gross margins above 52%, and providing quantified evidence of Amazon Bio Discovery conversion. Failure on any of these fronts would likely lead to a sharp de-rating, as the current price embeds optimistic assumptions. Therefore, investors should not chase this news; waiting for a pullback toward the $78 entry level or concrete financial proof is more prudent.

Thesis delta

The core thesis remains a WAIT rating: Twist has a real manufacturing moat but the stock price has outpaced fundamental proof. This new Lilly TuneLab collaboration does not materially change the financial outlook because it lacks disclosed economics and adds to the already crowded AI-discovery narrative. The next filing remains the critical checkpoint; until then, no change to the attractive entry level of $78 or the trim level of $112.